Full-Time

Operations

Pricing, & Analytics Associate Director, Pove, Gtn

Confirmed live in the last 24 hours

Vertex Pharmaceuticals

Vertex Pharmaceuticals

1,001-5,000 employees

Develops medicines for serious diseases

Compensation Overview

$164k - $246k/yr

+ Bonus + Equity Awards

Senior, Expert

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid-Eligible: work remotely up to two days per week; or work five days per week on-site with ad hoc flexibility.

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
SAS
SQL
SAP Products
Oracle
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • Prior experience in developing short and long term commercial forecasts, GTN models, pricing and contracting break-even analysis
  • Excellent working knowledge of the evolving pricing & reimbursement dynamics and health system environment for specialty, rare and transformative therapies, such as cell and gene therapy
  • Track record of producing insights and analysis based on Government Pricing (i.e; Medicaid, Medicare, 340B) data sets and communicating impacts and sensitivity analysis to senior management
  • Demonstrated understanding of contracting with PBMs, trade & distribution partners and strategies for value-driven pricing and reimbursements
  • Working knowledge and familiarity of syndicated Market Access databases (IQVIA, MMIT etc.)
  • Exposure and understanding of financial systems (such as Oracle, Hyperion, SAP etc.)
  • Experienced in complex Excel modeling and executing on PowerPoint presentations for senior management
  • Proficient in analyzing large data sets such as transactional or claims data, using a statistical analysis software package (e.g., SAS or equivalent) or SQL interface
  • Strong analytical and business acumen: intellectual curiosity, motivation, and ability to structure problems, diagnose issues and triangulate with multiple approaches while keeping sight of the “big picture”
  • Excellent communication and presentation skills to influence and collaborate with a diverse stakeholder community to achieve actionable and timely results, through establishing strong and sustainable relationships
Responsibilities
  • Builds, improves, and manages best-in-class models (i.e; GTN forecast) for commercial assets in the Vertex portfolio
  • Generates insights and leads complex analyses to address strategic questions, business cases, government policy changes in the industry and innovative reimbursement approaches such as value-based agreements throughout product lifecycle
  • Provides a high degree of support for the monthly and annual forecasting process, focusing on the current year and the following year, and project net revenue by modeling numerous underlying GTN drivers, ensuring quality of output and recommendations, as well as timeliness and business relevance of decision support deliverables
  • Delivers robust quantitative forecast assessments of managed care segment discount mix with clear articulation of the key drivers, sensitivities, risks, and opportunities and materials for quarterly earnings calls
  • Provides support for the annual long-range planning (LRP) process, which plays a key role in strategic and tactical planning. The LRP process requires substantial cross-functional collaboration to collect and integrate inputs, across all current and future markets
  • Integrates relevant pricing and utilization data and information from various sources and databases to develop business case analysis, reporting, scorecards, etc.
  • Works collaboratively with stakeholders including but not limited to Market Access, Public Affairs, Commercial Legal, US Sales & Marketing, Global Pricing & Market Access, FP&A, Commercial Sales Operations and Forecasting, Accounting, etc. to ensure transparency and collaboration across key decisions
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, focusing on conditions like cystic fibrosis. The company conducts extensive research and development to create new drugs, often collaborating with other biotech firms to enhance its therapeutic offerings. One of its notable products is ivacaftor, which has shown effectiveness in treating cystic fibrosis. Vertex differentiates itself from competitors through its commitment to scientific innovation and strategic partnerships that expand its research capabilities. The goal of Vertex Pharmaceuticals is to improve the quality of life for patients with severe and life-threatening conditions by bringing effective treatments to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex's EU approval expands its cystic fibrosis treatment market.
  • Partnerships with Arbor and Orna enhance Vertex's gene therapy capabilities.
  • Increased rare disease research funding supports Vertex's R&D efforts.

What critics are saying

  • Competition in cystic fibrosis treatments threatens Vertex's market share.
  • High R&D costs and trial delays could strain Vertex's finances.
  • Regulatory challenges may limit Vertex's drug market expansion.

What makes Vertex Pharmaceuticals unique

  • Vertex focuses on transformative medicines for serious diseases, like cystic fibrosis.
  • The company invests heavily in R&D and strategic biotech partnerships.
  • Vertex's innovative cell and gene therapies set it apart in the biotech industry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Company News

BioSpace
Apr 14th, 2025
Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex researcher, Paul Negulescu Ph.D., receives the 2025 Canada Gairdner International Award for pioneering Research and discovery of medicines for Cystic Fibrosis.

Biz Owner Daily
Apr 7th, 2025
EU Approves Expanded Label for Vertex Pharmaceuticals' Cystic Fibrosis Treatment

Vertex Pharmaceuticals has received approval from the European Union to broaden the label for its cystic fibrosis treatment.

Slater Sentinel
Mar 23rd, 2025
Stevens Capital Management LP Makes New $829,000 Investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Stevens Capital Management LP makes new $829,000 investment in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Investing.com
Mar 20th, 2025
BMO maintains Vertex stock Market Perform rating and $41 target

The reaffirmation of the rating and target came after Vertex held its first analyst day since its initial public offering in 2020.

Stat News
Mar 18th, 2025
Genetics expert is first NIH director to leave under Trump

He will be replaced on an interim basis by Director Ian Smith, a former Vertex Pharmaceuticals executive.